The next-generation sequencing (NGS)-based panel consists of 50 cancer-specific genes that could add diagnostic, prognostic and therapeutic value to personalised care.
“INVIEW ONCOPANEL was the lone missing member of our cancer research and diagnostics portfolio,” said Dr Markus Benz, COO of GATC Biotech. “The service perfectly complements our liquid biopsy-based assay GATCLIQUID ONCOPANEL. It enables researchers and clinicians to screen not only liquid biopsy samples, but also tissue biopsy samples for genomic alterations. These carefully selected genes can help characterise a patient’s tumour and identify the most suitable treatment course on a case-by-case basis.”
With the rising need for validation of non-invasive liquid biopsies, researchers can now evaluate the concordance in mutation profiles from tumour tissue samples with INVIEW ONCOPANEL and from liquid biopsy samples with GATCLIQUID ONCOPANEL. Both cancer sets consist of more than 200 clinically actionable regions on 50 cancer-specific genes with strong predictive and prognostic potential. The targeted cancer-related genes include well-known tumour activators, tumour suppressors and biomarkers of drug resistance.
“By providing cost-efficient detection of mutations in key cancer drivers, we hope to draw the most meaningful molecular information out of invasive, but necessary tissue biopsies,” added Dr Benz. “With the ability to perform comparative studies on tumour tissue and plasma-based patient samples under diagnostic conditions, we also aim to contribute evidence to proof-of-concept studies that are needed to implement liquid biopsies in clinical settings.”
INVIEW ONCOPANEL, which is a standardised sample-to-data solution, applies proprietary protocols for low-input DNA extraction from precious formalin-fixed, paraffin-embedded (FFPE) or fresh tissue samples. Optimised workflows carried out on leading technologies consistently result in extraordinarily high sequence coverage, uniformity and sensitivity that are needed to profile solid tumours and support tailored treatment decisions with absolute confidence.
Please visit www.gatc-biotech.com for more information about genomic innovation – Made in Germany.
Dr. Helge Schnerr
GATC Biotech AG
Phone: +49 (0) 7531 81 60 4154